Alzheimer’s Disease/Dementia News

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.

An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.

Endovascular therapy was linked with improved outcomes across five cognitive tests in those with acute ischemic stroke, according to research published in Neurology.

The Alzheimer’s Drug Discovery Foundation has invested $5 million in Coya Therapeutics to help accelerate development and advance drugs to prevent, treat and cure Alzheimer’s disease and related dementias.

Women diagnosed with preeclampsia were 2.6 times more likely to develop early-onset dementia during 9 years of follow-up compared with women who did not have a hypertensive disorder of pregnancy, according to registry data.

Otsuka Pharmaceutical has terminated its development of AVP-786, a novel compound that was being researched as a potential treatment for patients with agitation due to Alzheimer’s disease, according to a company-issued press release.

Alzheon Inc. has enrolled patients who completed either phase 2 or phase 3 trials to evaluate ALZ-801 as a treatment for early Alzheimer’s disease in long-term study extensions, according to a company-issued press release.

Patients with both diabetes and CAD appeared at significantly greater risk for dementia, especially vascular dementia, according to study findings published in European Journal of Preventive Cardiology.

Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.